Skip to main content
Erschienen in: Pediatric Nephrology 12/2018

29.11.2017 | Review

Disruptive technological advances in vascular access for dialysis: an overview

verfasst von: Wee-Song Yeo, Qin Xiang Ng

Erschienen in: Pediatric Nephrology | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

End-stage kidney disease (ESKD), one of the most prevalent diseases in the world and with increasing incidence, is associated with significant morbidity and mortality. Current available modes of renal replacement therapy (RRT) include dialysis and renal transplantation. Though renal transplantation is the preferred and ideal mode of RRT, this modality may not be available to all patients with ESKD. Moreover, renal transplant recipients are constantly at risk of complications associated with immunosuppression and immunosuppressant use, and posttransplant lymphoproliferative disorder. Dialysis may be the only available modality in certain patients. However, dialysis has its limitations, which include issues associated with lack of vascular access, risks of infections and vascular thrombosis, decreased quality of life, and absence of biosynthetic functions of the kidney. In particular, the creation and maintenance of hemodialysis vascular access in children poses a unique set of challenges to the pediatric nephrologist owing to the smaller vessel diameters and vascular hyperreactivity compared with adult patients. Vascular access issues continue to be one of the major limiting factors prohibiting the delivery of adequate dialysis in ESKD patients and is the Achilles’ heel of hemodialysis. This review aims to provide a critical overview of disruptive technological advances and innovations for vascular access. Novel strategies in preventing neointimal hyperplasia, novel bioengineered products, grafts and devices for vascular access will be discussed. The potential impact of these solutions on improving the morbidity encountered by dialysis patients will also be examined.
Literatur
1.
Zurück zum Zitat Couser WG, Remuzzi G, Mendis S, Tonelli M (2011) The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 80:1258–1270CrossRefPubMed Couser WG, Remuzzi G, Mendis S, Tonelli M (2011) The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 80:1258–1270CrossRefPubMed
2.
Zurück zum Zitat The Lancet (2013) The global issue of kidney disease. Lancet 382:101 The Lancet (2013) The global issue of kidney disease. Lancet 382:101
3.
Zurück zum Zitat Zaritsky JJ, Salusky IB, Gales B, Ramos G, Atkinson J, Allestead A, Brandt ML, Goldstein SL (2008) Vascular access complications in long-term pediatric hemodialysis patients. Pediatr Nephrol 23:2061–2065CrossRefPubMed Zaritsky JJ, Salusky IB, Gales B, Ramos G, Atkinson J, Allestead A, Brandt ML, Goldstein SL (2008) Vascular access complications in long-term pediatric hemodialysis patients. Pediatr Nephrol 23:2061–2065CrossRefPubMed
4.
Zurück zum Zitat Hayes WN, Watson AR, Callaghan N, Wright E, Stefanidis CJ, European Pediatric Dialysis Working Group (2012) Vascular access: choice and complications in European paediatric haemodialysis units. Pediatr Nephrol 27:999–1004CrossRefPubMed Hayes WN, Watson AR, Callaghan N, Wright E, Stefanidis CJ, European Pediatric Dialysis Working Group (2012) Vascular access: choice and complications in European paediatric haemodialysis units. Pediatr Nephrol 27:999–1004CrossRefPubMed
5.
Zurück zum Zitat Schaefer F, Feneberg R, Aksu N, Donmez O, Sadikoglu B, Alexander SR, Mir S, Ha IS, Fischbach M, Simkova E, Watson AR, Moller K, von Baum H, Warady BA (2007) Worldwide variation of dialysis-associated peritonitis in children. Kidney Int 72:1374–1379CrossRefPubMed Schaefer F, Feneberg R, Aksu N, Donmez O, Sadikoglu B, Alexander SR, Mir S, Ha IS, Fischbach M, Simkova E, Watson AR, Moller K, von Baum H, Warady BA (2007) Worldwide variation of dialysis-associated peritonitis in children. Kidney Int 72:1374–1379CrossRefPubMed
6.
Zurück zum Zitat Sethna CB, Bryant K, Munshi R, Warady BA, Richardson T, Lawlor J, Newland JG, Neu A, SCOPE Investigators (2016) Risk factors for and outcomes of catheter-associated peritonitis in children: the SCOPE collaborative. Clin J Am Soc Nephrol 11:1590–1596CrossRefPubMedPubMedCentral Sethna CB, Bryant K, Munshi R, Warady BA, Richardson T, Lawlor J, Newland JG, Neu A, SCOPE Investigators (2016) Risk factors for and outcomes of catheter-associated peritonitis in children: the SCOPE collaborative. Clin J Am Soc Nephrol 11:1590–1596CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Wartman SM, Rosen D, Woo K, Gradman WS, Weaver FA, Rowe V (2014) Outcomes with arteriovenous fistulas in a pediatric population. J Vasc Surg 60:170–174CrossRefPubMed Wartman SM, Rosen D, Woo K, Gradman WS, Weaver FA, Rowe V (2014) Outcomes with arteriovenous fistulas in a pediatric population. J Vasc Surg 60:170–174CrossRefPubMed
8.
Zurück zum Zitat Regus S, Almási-Sperling V, Lang W (2016) Pediatric patients undergoing arteriovenous fistula surgery without intraoperative heparin. J Vasc Access 17:494–498CrossRefPubMed Regus S, Almási-Sperling V, Lang W (2016) Pediatric patients undergoing arteriovenous fistula surgery without intraoperative heparin. J Vasc Access 17:494–498CrossRefPubMed
9.
Zurück zum Zitat Goldstein SL, Graham N, Burwinkle T, Warady B, Farrah R, Varni JW (2006) Health-related quality of life in pediatric patients with ESRD. Pediatr Nephrol 21:846–850CrossRefPubMed Goldstein SL, Graham N, Burwinkle T, Warady B, Farrah R, Varni JW (2006) Health-related quality of life in pediatric patients with ESRD. Pediatr Nephrol 21:846–850CrossRefPubMed
10.
Zurück zum Zitat Kostoff RN, Boylan R, Simons GR (2004) Disruptive technology roadmaps. Technol Forecast Soc Chang 71:141–159CrossRef Kostoff RN, Boylan R, Simons GR (2004) Disruptive technology roadmaps. Technol Forecast Soc Chang 71:141–159CrossRef
11.
Zurück zum Zitat Yu D, Hang CC (2011) Creating technology candidates for disruptive innovation: generally applicable R&D strategies. Technovation 31:401–410CrossRef Yu D, Hang CC (2011) Creating technology candidates for disruptive innovation: generally applicable R&D strategies. Technovation 31:401–410CrossRef
12.
Zurück zum Zitat Kolff WJ, Berk HTJ (1943) De kunstmatige nier; een dialysator met groot oppervlak. Ned Tijdschr Geneeskd 87:1684 Kolff WJ, Berk HTJ (1943) De kunstmatige nier; een dialysator met groot oppervlak. Ned Tijdschr Geneeskd 87:1684
13.
Zurück zum Zitat Broers H (2006) Inventor for life, the story of W. J. Kolff, father of artificial organs. B&V media, Kampen Broers H (2006) Inventor for life, the story of W. J. Kolff, father of artificial organs. B&V media, Kampen
14.
Zurück zum Zitat Kolff W (1946) De kunstmatige nier. Kok, Kampen Kolff W (1946) De kunstmatige nier. Kok, Kampen
15.
Zurück zum Zitat Vienken J (2009) ‘Bioengineering for life’: a tribute to Willem Johan Kolff. Nephrol Dial Transplant 24:2299–2301CrossRefPubMed Vienken J (2009) ‘Bioengineering for life’: a tribute to Willem Johan Kolff. Nephrol Dial Transplant 24:2299–2301CrossRefPubMed
16.
Zurück zum Zitat Schwab SJ (2007) Hemodialysis vascular access: the Achilles’ heel remains. Kidney Int 72:665–666CrossRefPubMed Schwab SJ (2007) Hemodialysis vascular access: the Achilles’ heel remains. Kidney Int 72:665–666CrossRefPubMed
17.
Zurück zum Zitat Akoh JA, Hakim NS (1999) Preserving function and long-term patency of dialysis access. Ann R Coll Surg Engl 81:339–342PubMedPubMedCentral Akoh JA, Hakim NS (1999) Preserving function and long-term patency of dialysis access. Ann R Coll Surg Engl 81:339–342PubMedPubMedCentral
18.
Zurück zum Zitat Valliant A, McComb K (2015) Vascular access monitoring and surveillance: an update. Adv Chronic Kidney Dis 22:446–452CrossRefPubMed Valliant A, McComb K (2015) Vascular access monitoring and surveillance: an update. Adv Chronic Kidney Dis 22:446–452CrossRefPubMed
19.
Zurück zum Zitat Allon M (2004) Dialysis catheter-related bacteremia: treatment and prophylaxis. Am J Kidney Dis 44:779–791CrossRefPubMed Allon M (2004) Dialysis catheter-related bacteremia: treatment and prophylaxis. Am J Kidney Dis 44:779–791CrossRefPubMed
20.
Zurück zum Zitat Allon M, Robbin ML (2002) Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. Kidney Int 62:1109–1124CrossRefPubMed Allon M, Robbin ML (2002) Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. Kidney Int 62:1109–1124CrossRefPubMed
21.
Zurück zum Zitat Lok CE (2007) Fistula first initiative: advantages and pitfalls. Clin J Am Soc Nephrol 2:1043–1053CrossRefPubMed Lok CE (2007) Fistula first initiative: advantages and pitfalls. Clin J Am Soc Nephrol 2:1043–1053CrossRefPubMed
22.
Zurück zum Zitat Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B, Wolfe RA, Goodkin DA, Held PJ (2002) Vascular access use in Europe and the United States: results from the DOPPS. Kidney Int 61:305–316CrossRefPubMed Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B, Wolfe RA, Goodkin DA, Held PJ (2002) Vascular access use in Europe and the United States: results from the DOPPS. Kidney Int 61:305–316CrossRefPubMed
23.
Zurück zum Zitat Bradbury BD, Chen F, Furniss A, Pisoni RL, Keen M, Mapes D, Krishnan M (2009) Conversion of vascular access type among incident hemodialysis patients: description and association with mortality. Am J Kidney Dis 53:804–814CrossRefPubMed Bradbury BD, Chen F, Furniss A, Pisoni RL, Keen M, Mapes D, Krishnan M (2009) Conversion of vascular access type among incident hemodialysis patients: description and association with mortality. Am J Kidney Dis 53:804–814CrossRefPubMed
24.
Zurück zum Zitat Lacson E Jr, Wang W, Lazarus JM, Hakim RM (2009) Change in vascular access and mortality in maintenance hemodialysis patients. Am J Kidney Dis 54:912–921CrossRefPubMed Lacson E Jr, Wang W, Lazarus JM, Hakim RM (2009) Change in vascular access and mortality in maintenance hemodialysis patients. Am J Kidney Dis 54:912–921CrossRefPubMed
25.
Zurück zum Zitat Vassalotti JA, Jennings WC, Beathard GA, Neumann M, Caponi S, Fox CH, Spergel LM, Fistula First Breakthrough Initiative Community Education Committee (2012) Fistula first breakthrough initiative: targeting catheter last in fistula first. Semin Dial 25:303–310CrossRefPubMed Vassalotti JA, Jennings WC, Beathard GA, Neumann M, Caponi S, Fox CH, Spergel LM, Fistula First Breakthrough Initiative Community Education Committee (2012) Fistula first breakthrough initiative: targeting catheter last in fistula first. Semin Dial 25:303–310CrossRefPubMed
27.
Zurück zum Zitat Schwab SJ, Harrington JT, Singh A, Roher R, Shohaib SA, Perrone RD, Meyer K, Beasley D (1999) Vascular access for hemodialysis. Kidney Int 55:2078–2090CrossRefPubMed Schwab SJ, Harrington JT, Singh A, Roher R, Shohaib SA, Perrone RD, Meyer K, Beasley D (1999) Vascular access for hemodialysis. Kidney Int 55:2078–2090CrossRefPubMed
28.
Zurück zum Zitat Feldman HI, Joffe M, Rosas SE, Burns JE, Knauss J, Brayman K (2003) Predictors of successful arteriovenous fistula maturation. Am J Kidney Dis 42:1000–1012CrossRefPubMed Feldman HI, Joffe M, Rosas SE, Burns JE, Knauss J, Brayman K (2003) Predictors of successful arteriovenous fistula maturation. Am J Kidney Dis 42:1000–1012CrossRefPubMed
29.
Zurück zum Zitat Lacson E Jr, Lazarus JM, Himmelfarb J, Ikizler TA, Hakim RM (2007) Balancing fistula first with catheters last. Am J Kidney Dis 50:379–395CrossRefPubMed Lacson E Jr, Lazarus JM, Himmelfarb J, Ikizler TA, Hakim RM (2007) Balancing fistula first with catheters last. Am J Kidney Dis 50:379–395CrossRefPubMed
30.
Zurück zum Zitat Huijbregts HJ, Bots ML, Wittens CH, Schrama YC, Moll FL, Blankestijn PJ; CIMINO study group (2008) Hemodialysis arteriovenous fistula patency revisited: results of a prospective, multicenter initiative. Clin J Am Soc Nephrol 3:714-719 Huijbregts HJ, Bots ML, Wittens CH, Schrama YC, Moll FL, Blankestijn PJ; CIMINO study group (2008) Hemodialysis arteriovenous fistula patency revisited: results of a prospective, multicenter initiative. Clin J Am Soc Nephrol 3:714-719
31.
Zurück zum Zitat Maya ID, Allon M (2005) Outcomes of tunneled femoral hemodialysis catheters: comparison with internal jugular vein catheters. Kidney Int 68:2886–2889CrossRefPubMed Maya ID, Allon M (2005) Outcomes of tunneled femoral hemodialysis catheters: comparison with internal jugular vein catheters. Kidney Int 68:2886–2889CrossRefPubMed
32.
Zurück zum Zitat Huber TS, Carter JW, Carter RL, Seeger JM (2003) Patency of autogenous and polytetrafluoroethylene upper extremity arteriovenous hemodialysis accesses: a systematic review. J Vasc Surg 38:1005–1011CrossRefPubMed Huber TS, Carter JW, Carter RL, Seeger JM (2003) Patency of autogenous and polytetrafluoroethylene upper extremity arteriovenous hemodialysis accesses: a systematic review. J Vasc Surg 38:1005–1011CrossRefPubMed
33.
Zurück zum Zitat Roy-Chaudhury P, Sukhatme VP, Cheung AK (2006) Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol 17:1112–1127CrossRefPubMed Roy-Chaudhury P, Sukhatme VP, Cheung AK (2006) Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol 17:1112–1127CrossRefPubMed
34.
Zurück zum Zitat Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, Dember LM, Himmelfarb J, Gassman JJ, Greene T, Radeva MK, Davidson IJ, Ikizler TA, Braden GL, Fenves AZ, Kaufman JS, Cotton JR Jr, Martin KJ, JW MN, Rahman A, Lawson JH, Whiting JF, Hu B, Meyers CM, Kusek JW, Feldman HI, DAC Study Group (2009) Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med 360:2191–2201CrossRefPubMedPubMedCentral Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, Dember LM, Himmelfarb J, Gassman JJ, Greene T, Radeva MK, Davidson IJ, Ikizler TA, Braden GL, Fenves AZ, Kaufman JS, Cotton JR Jr, Martin KJ, JW MN, Rahman A, Lawson JH, Whiting JF, Hu B, Meyers CM, Kusek JW, Feldman HI, DAC Study Group (2009) Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med 360:2191–2201CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Lok CE, Sontrop JM, Tomlinson G, Rajan D, Cattral M, Oreopoulos G, Harris J, Moist L (2013) Cumulative patency of contemporary fistulas versus grafts (2000-2010). Clin J Am Soc Nephrol 8:810–818CrossRefPubMedPubMedCentral Lok CE, Sontrop JM, Tomlinson G, Rajan D, Cattral M, Oreopoulos G, Harris J, Moist L (2013) Cumulative patency of contemporary fistulas versus grafts (2000-2010). Clin J Am Soc Nephrol 8:810–818CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat CDC (2011) Vital signs: central line-associated blood stream infections—United States, 2001, 2008, and 2009. Morb Mortal Wkly Rep (MMWR) 60:243–248 CDC (2011) Vital signs: central line-associated blood stream infections—United States, 2001, 2008, and 2009. Morb Mortal Wkly Rep (MMWR) 60:243–248
37.
Zurück zum Zitat Tokars JI, Miller ER, Stein G (2002) New national surveillance system for hemodialysis-associated infections: initial results. Am J Infect Control 30:288–295CrossRefPubMed Tokars JI, Miller ER, Stein G (2002) New national surveillance system for hemodialysis-associated infections: initial results. Am J Infect Control 30:288–295CrossRefPubMed
38.
Zurück zum Zitat Ishani A, Collins AJ, Herzog CA, Foley RN (2005) Septicemia, access and cardiovascular disease in dialysis patients: the USRDS wave 2 study. Kidney Int 68:311–318CrossRefPubMed Ishani A, Collins AJ, Herzog CA, Foley RN (2005) Septicemia, access and cardiovascular disease in dialysis patients: the USRDS wave 2 study. Kidney Int 68:311–318CrossRefPubMed
39.
Zurück zum Zitat Agarwal AK, Patel BM, Haddad NJ (2007) Central vein stenosis: a nephrologist’s perspective. Semin Dial 20:53–62CrossRefPubMed Agarwal AK, Patel BM, Haddad NJ (2007) Central vein stenosis: a nephrologist’s perspective. Semin Dial 20:53–62CrossRefPubMed
40.
Zurück zum Zitat Lee T, Barker J, Allon M (2005) Tunneled catheters in hemodialysis patients: reasons and subsequent outcomes. Am J Kidney Dis 46:501–508CrossRefPubMed Lee T, Barker J, Allon M (2005) Tunneled catheters in hemodialysis patients: reasons and subsequent outcomes. Am J Kidney Dis 46:501–508CrossRefPubMed
41.
Zurück zum Zitat MacRae JM, Ahmed A, Johnson N, Levin A, Kiaii M (2005) Central vein stenosis: a common problem in patients on hemodialysis. ASAIO J 51:77–81CrossRefPubMed MacRae JM, Ahmed A, Johnson N, Levin A, Kiaii M (2005) Central vein stenosis: a common problem in patients on hemodialysis. ASAIO J 51:77–81CrossRefPubMed
42.
Zurück zum Zitat Roy-Chaudhury P, Lee TC (2007) Vascular stenosis: biology and interventions. Curr Opin Nephrol Hypertens 16:516–522CrossRefPubMed Roy-Chaudhury P, Lee TC (2007) Vascular stenosis: biology and interventions. Curr Opin Nephrol Hypertens 16:516–522CrossRefPubMed
43.
Zurück zum Zitat Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB (2008) Understanding the pathophysiology of hemodialysis access problems as a prelude to developing innovative therapies. Nat Clin Pract Nephrol 4:628–638CrossRefPubMed Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB (2008) Understanding the pathophysiology of hemodialysis access problems as a prelude to developing innovative therapies. Nat Clin Pract Nephrol 4:628–638CrossRefPubMed
44.
Zurück zum Zitat Franano FN, Hance KA, Henry C, Bland K, Burke S (2007) PRT-201 dilates outflow veins and improves maturation rates in a rabbit model of AVF. Nephrol Dial Transplant 22:vi155–vi156 Franano FN, Hance KA, Henry C, Bland K, Burke S (2007) PRT-201 dilates outflow veins and improves maturation rates in a rabbit model of AVF. Nephrol Dial Transplant 22:vi155–vi156
45.
Zurück zum Zitat Amabile PG, Wong H, Uy M, Boroumand S, Elkins CJ, Yuksel E, Waugh JM, Dake MD (2002) In vivo vascular engineering of vein grafts: directed migration of smooth muscle cells by perivascular release of elastase limits neointimal proliferation. J Vasc Interv Radiol 13:709–715CrossRefPubMed Amabile PG, Wong H, Uy M, Boroumand S, Elkins CJ, Yuksel E, Waugh JM, Dake MD (2002) In vivo vascular engineering of vein grafts: directed migration of smooth muscle cells by perivascular release of elastase limits neointimal proliferation. J Vasc Interv Radiol 13:709–715CrossRefPubMed
46.
Zurück zum Zitat Wong AH, Waugh JM, Amabile PG, Yuksel E, Dake MD (2002) In vivo vascular engineering: directed migration of smooth muscle cells to limit neointima. Tissue Eng 8:189–199CrossRefPubMed Wong AH, Waugh JM, Amabile PG, Yuksel E, Dake MD (2002) In vivo vascular engineering: directed migration of smooth muscle cells to limit neointima. Tissue Eng 8:189–199CrossRefPubMed
47.
Zurück zum Zitat Dwivedi AJ, Roy-Chaudhury P, Peden EK, Browne BJ, Ladenheim ED, Scavo VA, Gustafson PN, Wong MD, Magill M, Lindow F, Blair AT, Jaff MR, Franano FN, Burke SK (2014) Application of human type I pancreatic elastase (PRT-201) to the venous anastomosis of arteriovenous grafts in patients with chronic kidney disease. J Vasc Access 15:376–384CrossRefPubMedPubMedCentral Dwivedi AJ, Roy-Chaudhury P, Peden EK, Browne BJ, Ladenheim ED, Scavo VA, Gustafson PN, Wong MD, Magill M, Lindow F, Blair AT, Jaff MR, Franano FN, Burke SK (2014) Application of human type I pancreatic elastase (PRT-201) to the venous anastomosis of arteriovenous grafts in patients with chronic kidney disease. J Vasc Access 15:376–384CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Paulson WD, Kipshidze N, Kipiani K, Beridze N, DeVita MV, Shenoy S, Iyer SS (2012) Safety and efficacy of local periadventitial delivery of sirolimus for improving hemodialysis graft patency: first human experience with a sirolimus-eluting collagen membrane (Coll-R). Nephrol Dial Transplant 27:1219–1224CrossRefPubMed Paulson WD, Kipshidze N, Kipiani K, Beridze N, DeVita MV, Shenoy S, Iyer SS (2012) Safety and efficacy of local periadventitial delivery of sirolimus for improving hemodialysis graft patency: first human experience with a sirolimus-eluting collagen membrane (Coll-R). Nephrol Dial Transplant 27:1219–1224CrossRefPubMed
49.
Zurück zum Zitat Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP, Snead D, Mauri L, Cutlip DE, Sousa E (2007) Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 50:1299–1304CrossRefPubMed Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP, Snead D, Mauri L, Cutlip DE, Sousa E (2007) Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 50:1299–1304CrossRefPubMed
50.
Zurück zum Zitat Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Popma JJ, Teirstein PS, Cohen SA, Wang H, Cutlip DE, Moses JW (2009) Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-eluting stent in de-novo native coronary lesions) trial. J Am Coll Cardiol 53:1488–1497CrossRefPubMed Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Popma JJ, Teirstein PS, Cohen SA, Wang H, Cutlip DE, Moses JW (2009) Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-eluting stent in de-novo native coronary lesions) trial. J Am Coll Cardiol 53:1488–1497CrossRefPubMed
51.
Zurück zum Zitat Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr, Nater C, Hruban RH, Rezai B, Abella BS, Bunge KE, Kinsella JL, Sollott SJ, Lakatta EG, Brinker JA, Hunter WL, Froehlich JP (2001) Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103:2289–2295CrossRefPubMed Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr, Nater C, Hruban RH, Rezai B, Abella BS, Bunge KE, Kinsella JL, Sollott SJ, Lakatta EG, Brinker JA, Hunter WL, Froehlich JP (2001) Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103:2289–2295CrossRefPubMed
52.
Zurück zum Zitat Hong MK, Mintz GS, Lee CW, Song JM, Han KH, Kang DH, Song JK, Kim JJ, Weissman NJ, Fearnot NE, Park SW, Park SJ, ASian Paclitaxel-Eluting Stent Clinical Trial (2003) Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-eluting stent clinical trial (ASPECT). Circulation 107(4):517–520CrossRefPubMed Hong MK, Mintz GS, Lee CW, Song JM, Han KH, Kang DH, Song JK, Kim JJ, Weissman NJ, Fearnot NE, Park SW, Park SJ, ASian Paclitaxel-Eluting Stent Clinical Trial (2003) Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-eluting stent clinical trial (ASPECT). Circulation 107(4):517–520CrossRefPubMed
53.
Zurück zum Zitat Jeroudi OM, Abdel-Karim AR, Michael TT, Lichtenwalter C, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Raghunathan D, DaSilva M, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S, Brilakis ES (2011) Paclitaxel-eluting stents reduce neointimal hyperplasia compared to bare metal stents in saphenous vein grafts: intravascular ultrasonography analysis of the SOS (stenting of Saphenous vein grafts) trial. Euro Intervention 7:948–954PubMed Jeroudi OM, Abdel-Karim AR, Michael TT, Lichtenwalter C, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Raghunathan D, DaSilva M, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S, Brilakis ES (2011) Paclitaxel-eluting stents reduce neointimal hyperplasia compared to bare metal stents in saphenous vein grafts: intravascular ultrasonography analysis of the SOS (stenting of Saphenous vein grafts) trial. Euro Intervention 7:948–954PubMed
54.
Zurück zum Zitat Lee CH, Yu CY, Chang SH, Hung KC, Liu SJ, Wang CJ, Hsu MY, Hsieh IC, Chen WJ, Ko YS, Wen MS (2014) Promoting endothelial recovery and reducing neointimal hyperplasia using sequential-like release of acetylsalicylic acid and paclitaxel-loaded biodegradable stents. Int J Nanomedicine 9:4117–4133CrossRefPubMedPubMedCentral Lee CH, Yu CY, Chang SH, Hung KC, Liu SJ, Wang CJ, Hsu MY, Hsieh IC, Chen WJ, Ko YS, Wen MS (2014) Promoting endothelial recovery and reducing neointimal hyperplasia using sequential-like release of acetylsalicylic acid and paclitaxel-loaded biodegradable stents. Int J Nanomedicine 9:4117–4133CrossRefPubMedPubMedCentral
55.
Zurück zum Zitat Katsanos K, Karnabatidis D, Kitrou P, Spiliopoulos S, Christeas N, Siablis D (2012) Paclitaxel-coated balloon angioplasty vs. plain balloon dilation for the treatment of failing dialysis access: 6-month interim results from a prospective randomized controlled trial. J Endovasc Ther 19:263–272CrossRefPubMed Katsanos K, Karnabatidis D, Kitrou P, Spiliopoulos S, Christeas N, Siablis D (2012) Paclitaxel-coated balloon angioplasty vs. plain balloon dilation for the treatment of failing dialysis access: 6-month interim results from a prospective randomized controlled trial. J Endovasc Ther 19:263–272CrossRefPubMed
56.
Zurück zum Zitat Kitrou PM, Spiliopoulos S, Katsanos K, Papachristou E, Siablis D, Karnabatidis D (2015) Paclitaxel-coated versus plain balloon angioplasty for dysfunctional arteriovenous fistulae: one-year results of a prospective randomized controlled trial. J Vasc Interv Radiol 26:348–354CrossRefPubMed Kitrou PM, Spiliopoulos S, Katsanos K, Papachristou E, Siablis D, Karnabatidis D (2015) Paclitaxel-coated versus plain balloon angioplasty for dysfunctional arteriovenous fistulae: one-year results of a prospective randomized controlled trial. J Vasc Interv Radiol 26:348–354CrossRefPubMed
57.
Zurück zum Zitat Karunanithy N, Mesa IR, Dorling A, Calder F, Katsanos K, Semik V, Robinson E, Peacock J, Das N, Forman C, Lawman S, Steiner K, Wilkins CJ, Robson MG (2016) Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial. Trials 17:241CrossRefPubMedPubMedCentral Karunanithy N, Mesa IR, Dorling A, Calder F, Katsanos K, Semik V, Robinson E, Peacock J, Das N, Forman C, Lawman S, Steiner K, Wilkins CJ, Robson MG (2016) Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial. Trials 17:241CrossRefPubMedPubMedCentral
58.
Zurück zum Zitat Zilla P, Deutsch M, Meinhart J, Puschmann R, Eberl T, Minar E, Dudczak R, Lugmaier H, Schmidt P, Noszian I, Fischlein T (1994) Clinical in vitro endothelialization of femoropopliteal bypass grafts: an actuarial follow-up over three years. J Vasc Surg 19:540–548CrossRefPubMed Zilla P, Deutsch M, Meinhart J, Puschmann R, Eberl T, Minar E, Dudczak R, Lugmaier H, Schmidt P, Noszian I, Fischlein T (1994) Clinical in vitro endothelialization of femoropopliteal bypass grafts: an actuarial follow-up over three years. J Vasc Surg 19:540–548CrossRefPubMed
59.
Zurück zum Zitat Wilson JM, Birinyi LK, Salomon RN, Libby P, Callow AD, Mulligan RC (1989) Implantation of vascular grafts lined with genetically modified endothelial cells. Science 244:1344–1346CrossRefPubMed Wilson JM, Birinyi LK, Salomon RN, Libby P, Callow AD, Mulligan RC (1989) Implantation of vascular grafts lined with genetically modified endothelial cells. Science 244:1344–1346CrossRefPubMed
60.
Zurück zum Zitat Nathan A, Nugent MA, Edelman ER (1995) Tissue engineered perivascular endothelial cell implants regulate vascular injury. Proc Natl Acad Sci U S A 92:8130–8134CrossRefPubMedPubMedCentral Nathan A, Nugent MA, Edelman ER (1995) Tissue engineered perivascular endothelial cell implants regulate vascular injury. Proc Natl Acad Sci U S A 92:8130–8134CrossRefPubMedPubMedCentral
61.
Zurück zum Zitat Nugent HM, Rogers C, Edelman ER (1999) Endothelial implants inhibit intimal hyperplasia after porcine angioplasty. Circ Res 84:384–391CrossRefPubMed Nugent HM, Rogers C, Edelman ER (1999) Endothelial implants inhibit intimal hyperplasia after porcine angioplasty. Circ Res 84:384–391CrossRefPubMed
62.
Zurück zum Zitat Nugent HM, Sjin RT, White D, Milton LG, Manson RJ, Lawson JH, Edelman ER (2007) Adventitial endothelial implants reduce matrix metalloproteinase-2 expression and increase luminal diameter in porcine arteriovenous grafts. J Vasc Surg 46:548–556CrossRefPubMedPubMedCentral Nugent HM, Sjin RT, White D, Milton LG, Manson RJ, Lawson JH, Edelman ER (2007) Adventitial endothelial implants reduce matrix metalloproteinase-2 expression and increase luminal diameter in porcine arteriovenous grafts. J Vasc Surg 46:548–556CrossRefPubMedPubMedCentral
63.
Zurück zum Zitat Hughes D, Fu AA, Puggioni A, Glockner JF, Anwer B, McGuire AM, Mukhopadhyay D, Misra S (2009) Adventitial transplantation of blood outgrowth endothelial cells in porcine haemodialysis grafts alleviates hypoxia and decreases neointimal proliferation through a matrix metalloproteinase-9-mediated pathway--a pilot study. Nephrol Dial Transplant 24:85–96CrossRefPubMed Hughes D, Fu AA, Puggioni A, Glockner JF, Anwer B, McGuire AM, Mukhopadhyay D, Misra S (2009) Adventitial transplantation of blood outgrowth endothelial cells in porcine haemodialysis grafts alleviates hypoxia and decreases neointimal proliferation through a matrix metalloproteinase-9-mediated pathway--a pilot study. Nephrol Dial Transplant 24:85–96CrossRefPubMed
64.
Zurück zum Zitat Conte MS, Nugent HM, Gaccione P, Guleria I, Roy-Chaudhury P, Lawson JH (2009) Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: the V-HEALTH study. J Vasc Surg 50:1359–1368CrossRefPubMed Conte MS, Nugent HM, Gaccione P, Guleria I, Roy-Chaudhury P, Lawson JH (2009) Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: the V-HEALTH study. J Vasc Surg 50:1359–1368CrossRefPubMed
65.
Zurück zum Zitat Conte MS, Nugent HM, Gaccione P, Roy-Chaudhury P, Lawson JH (2011) Influence of diabetes and perivascular allogeneic endothelial cell implants on arteriovenous fistula remodeling. J Vasc Surg 54:1383–1389CrossRefPubMed Conte MS, Nugent HM, Gaccione P, Roy-Chaudhury P, Lawson JH (2011) Influence of diabetes and perivascular allogeneic endothelial cell implants on arteriovenous fistula remodeling. J Vasc Surg 54:1383–1389CrossRefPubMed
66.
Zurück zum Zitat L’Heureux N, Dusserre N, Konig G, Victor B, Keire P, Wight TN, Chronos NA, Kyles AE, Gregory CR, Hoyt G, Robbins RC, McAllister TN (2006) Human tissue-engineered blood vessels for adult arterial revascularization. Nat Med 12:361–365CrossRefPubMedPubMedCentral L’Heureux N, Dusserre N, Konig G, Victor B, Keire P, Wight TN, Chronos NA, Kyles AE, Gregory CR, Hoyt G, Robbins RC, McAllister TN (2006) Human tissue-engineered blood vessels for adult arterial revascularization. Nat Med 12:361–365CrossRefPubMedPubMedCentral
67.
Zurück zum Zitat L’Heureux N, Dusserre N, Marini A, Garrido S, de la Fuente L, McAllister T (2007) Technology insight: the evolution of tissue-engineered vascular grafts--from research to clinical practice. Nat Clin Pract Cardiovasc Med 4:389–395CrossRefPubMed L’Heureux N, Dusserre N, Marini A, Garrido S, de la Fuente L, McAllister T (2007) Technology insight: the evolution of tissue-engineered vascular grafts--from research to clinical practice. Nat Clin Pract Cardiovasc Med 4:389–395CrossRefPubMed
68.
Zurück zum Zitat McAllister TN, Dusserre N, Maruszewski M, L’heureux N (2008) Cell-based therapeutics from an economic perspective: primed for a commercial success or a research sinkhole? Regen Med 3:925–937CrossRefPubMed McAllister TN, Dusserre N, Maruszewski M, L’heureux N (2008) Cell-based therapeutics from an economic perspective: primed for a commercial success or a research sinkhole? Regen Med 3:925–937CrossRefPubMed
69.
Zurück zum Zitat Konig G, McAllister TN, Dusserre N, Garrido SA, Iyican C, Marini A, Fiorillo A, Avila H, Wystrychowski W, Zagalski K, Maruszewski M, Jones AL, Cierpka L, de la Fuente LM, L’Heureux N (2009) Mechanical properties of completely autologous human tissue engineered blood vessels compared to human saphenous vein and mammary artery. Biomaterials 30:1542–1550CrossRefPubMed Konig G, McAllister TN, Dusserre N, Garrido SA, Iyican C, Marini A, Fiorillo A, Avila H, Wystrychowski W, Zagalski K, Maruszewski M, Jones AL, Cierpka L, de la Fuente LM, L’Heureux N (2009) Mechanical properties of completely autologous human tissue engineered blood vessels compared to human saphenous vein and mammary artery. Biomaterials 30:1542–1550CrossRefPubMed
70.
Zurück zum Zitat McAllister TN, Maruszewski M, Garrido SA, Wystrychowski W, Dusserre N, Marini A, Zagalski K, Fiorillo A, Avila H, Manglano X, Antonelli J, Kocher A, Zembala M, Cierpka L, de la Fuente LM, L’heureux N (2009) Effectiveness of haemodialysis access with an autologous tissue-engineered vascular graft: a multicentre cohort study. Lancet 373:1440–1446CrossRefPubMed McAllister TN, Maruszewski M, Garrido SA, Wystrychowski W, Dusserre N, Marini A, Zagalski K, Fiorillo A, Avila H, Manglano X, Antonelli J, Kocher A, Zembala M, Cierpka L, de la Fuente LM, L’heureux N (2009) Effectiveness of haemodialysis access with an autologous tissue-engineered vascular graft: a multicentre cohort study. Lancet 373:1440–1446CrossRefPubMed
71.
Zurück zum Zitat McAllister T (2010) The evolution of tissue engineered vascular grafts: from research to clinical practice. Conf Proc IEEE Eng Med Biol Soc 2010:3589 McAllister T (2010) The evolution of tissue engineered vascular grafts: from research to clinical practice. Conf Proc IEEE Eng Med Biol Soc 2010:3589
72.
Zurück zum Zitat Peck MK, Dusserre N, Zagalski K, Garrido SA, Wystrychowski W, Glickman MH, Chronos NA, Cierpka L, L’Heureux N, McAllister TN (2011) New biological solutions for hemodialysis access. J Vasc Access 12:185–192CrossRefPubMed Peck MK, Dusserre N, Zagalski K, Garrido SA, Wystrychowski W, Glickman MH, Chronos NA, Cierpka L, L’Heureux N, McAllister TN (2011) New biological solutions for hemodialysis access. J Vasc Access 12:185–192CrossRefPubMed
73.
Zurück zum Zitat Peck M, Gebhart D, Dusserre N, McAllister TN, L’Heureux N (2012) The evolution of vascular tissue engineering and current state of the art. Cells Tissues Organs 195:144–158CrossRefPubMed Peck M, Gebhart D, Dusserre N, McAllister TN, L’Heureux N (2012) The evolution of vascular tissue engineering and current state of the art. Cells Tissues Organs 195:144–158CrossRefPubMed
74.
Zurück zum Zitat McAllister TN, Audley D, L’Heureux N (2012) Autologous cell therapies: challenges in US FDA regulation. Regen Med 7(6 Suppl):94–97CrossRefPubMed McAllister TN, Audley D, L’Heureux N (2012) Autologous cell therapies: challenges in US FDA regulation. Regen Med 7(6 Suppl):94–97CrossRefPubMed
75.
Zurück zum Zitat Wystrychowski W, McAllister TN, Zagalski K, Dusserre N, Cierpka L, L’Heureux N (2014) First human use of an allogeneic tissue-engineered vascular graft for hemodialysis access. J Vasc Surg 60:1353–1357CrossRefPubMed Wystrychowski W, McAllister TN, Zagalski K, Dusserre N, Cierpka L, L’Heureux N (2014) First human use of an allogeneic tissue-engineered vascular graft for hemodialysis access. J Vasc Surg 60:1353–1357CrossRefPubMed
76.
Zurück zum Zitat L’Heureux N, Letourneur D (2015) Clinical translation of tissue-engineered constructs for severe leg injuries. Ann Transl Med 3:134PubMedPubMedCentral L’Heureux N, Letourneur D (2015) Clinical translation of tissue-engineered constructs for severe leg injuries. Ann Transl Med 3:134PubMedPubMedCentral
77.
Zurück zum Zitat Dahl SL, Rhim C, Song YC, Niklason LE (2007) Mechanical properties and compositions of tissue engineered and native arteries. Ann Biomed Eng 35:348–355CrossRefPubMedPubMedCentral Dahl SL, Rhim C, Song YC, Niklason LE (2007) Mechanical properties and compositions of tissue engineered and native arteries. Ann Biomed Eng 35:348–355CrossRefPubMedPubMedCentral
78.
79.
Zurück zum Zitat Dahl SL, Vaughn ME, Hu JJ, Driessen NJ, Baaijens FP, Humphrey JD, Niklason LE (2008) A microstructurally motivated model of the mechanical behavior of tissue engineered blood vessels. Ann Biomed Eng 36:1782–1792CrossRefPubMedPubMedCentral Dahl SL, Vaughn ME, Hu JJ, Driessen NJ, Baaijens FP, Humphrey JD, Niklason LE (2008) A microstructurally motivated model of the mechanical behavior of tissue engineered blood vessels. Ann Biomed Eng 36:1782–1792CrossRefPubMedPubMedCentral
80.
Zurück zum Zitat Dahl SL, Kypson AP, Lawson JH, Blum JL, Strader JT, Li Y, Manson RJ, Tente WE, DiBernardo L, Hensley MT, Carter R, Williams TP, Prichard HL, Dey MS, Begelman KG, Niklason LE (2011) Readily available tissue-engineered vascular grafts. Sci Transl med 3:68ra9CrossRefPubMed Dahl SL, Kypson AP, Lawson JH, Blum JL, Strader JT, Li Y, Manson RJ, Tente WE, DiBernardo L, Hensley MT, Carter R, Williams TP, Prichard HL, Dey MS, Begelman KG, Niklason LE (2011) Readily available tissue-engineered vascular grafts. Sci Transl med 3:68ra9CrossRefPubMed
81.
Zurück zum Zitat Prichard HL, Manson RJ, DiBernardo L, Niklason LE, Lawson JH, Dahl SL (2011) An early study on the mechanisms that allow tissue-engineered vascular grafts to resist intimal hyperplasia. J Cardiovasc Transl Res 4:674–682CrossRefPubMedPubMedCentral Prichard HL, Manson RJ, DiBernardo L, Niklason LE, Lawson JH, Dahl SL (2011) An early study on the mechanisms that allow tissue-engineered vascular grafts to resist intimal hyperplasia. J Cardiovasc Transl Res 4:674–682CrossRefPubMedPubMedCentral
82.
Zurück zum Zitat Dahl SL, Blum JL, Niklason LE (2011) Bioengineered vascular grafts: can we make them off-the-shelf? Trends Cardiovasc Med 21:83–89CrossRefPubMed Dahl SL, Blum JL, Niklason LE (2011) Bioengineered vascular grafts: can we make them off-the-shelf? Trends Cardiovasc Med 21:83–89CrossRefPubMed
83.
Zurück zum Zitat Lawson JH, Glickman MH, Ilzecki M, Jakimowicz T, Jaroszynski A, Peden EK, Pilgrim AJ, Prichard HL, Guziewicz M, Przywara S, Szmidt J, Turek J, Witkiewicz W, Zapotoczny N, Zubilewicz T, Niklason LE (2016) Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials. Lancet 387:2026–2034CrossRefPubMedPubMedCentral Lawson JH, Glickman MH, Ilzecki M, Jakimowicz T, Jaroszynski A, Peden EK, Pilgrim AJ, Prichard HL, Guziewicz M, Przywara S, Szmidt J, Turek J, Witkiewicz W, Zapotoczny N, Zubilewicz T, Niklason LE (2016) Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials. Lancet 387:2026–2034CrossRefPubMedPubMedCentral
84.
Zurück zum Zitat L’Heureux N, McAllister TN, de la Fuente LM (2007) Tissue-engineered blood vessel for adult arterial revascularization. N Engl J Med 357:1451–1453CrossRefPubMed L’Heureux N, McAllister TN, de la Fuente LM (2007) Tissue-engineered blood vessel for adult arterial revascularization. N Engl J Med 357:1451–1453CrossRefPubMed
85.
Zurück zum Zitat National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1–S266 National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1–S266
86.
Zurück zum Zitat Hansbrough JF, Mozingo DW, Kealey GP, Davis M, Gidner A, Gentzkow GD (1997) Clinical trials of a biosynthetic temporary skin replacement, Dermagraft-transitional covering, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. J Burn Care Res 18:43–51CrossRef Hansbrough JF, Mozingo DW, Kealey GP, Davis M, Gidner A, Gentzkow GD (1997) Clinical trials of a biosynthetic temporary skin replacement, Dermagraft-transitional covering, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. J Burn Care Res 18:43–51CrossRef
Metadaten
Titel
Disruptive technological advances in vascular access for dialysis: an overview
verfasst von
Wee-Song Yeo
Qin Xiang Ng
Publikationsdatum
29.11.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 12/2018
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-017-3853-7

Weitere Artikel der Ausgabe 12/2018

Pediatric Nephrology 12/2018 Zur Ausgabe

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.